Edited by: Christopher Staley, University of Minnesota, USA (BMC Microbiology)
Jacques Ravel, University of Maryland, USA (Microbiome)
Sean Devlin, Memorial Sloan-Kettering Cancer Center, USA (BMC Cancer)
BMC Cancer, BMC Microbiology and Microbiome jointly present the ‘Microbiome and Cancer’ collection.
Pulmonary tuberculosis is a chronic infectious disease of the respiratory system. It is still one of the leading causes of death from a single infectious disease, but it has been stuck in the study of a single...
Lynch Syndrome (LS) is an inherited cancer predisposition syndrome defined by pathogenic variants in the mismatch repair (MMR) or EPCAM genes. In the United Kingdom, people with LS are advised to undergo biennial...
Prostate cancer (PCa) is the second most common cancer in men worldwide. The standard non-surgical approach for localized PCa is radiotherapy (RT), but one of the limitations of high-dose RT is the potential i...
Cancer patients experience gastrointestinal and behavioral symptoms, and are at increased risk of systemic infection and inflammation. These conditions are a major source of morbidity and decreased quality of ...
Cancer impacts millions of lives globally each year, with approximately 10 million cancer-related deaths recorded worldwide in 2020. Mounting research has recognised the human microbiome as a key area of inter...
The gut microbiome is implicated as a marker of response to immune checkpoint inhibitors (ICI) based on preclinical mouse models and preliminary observations in limited patient series. Furthermore, early stud...
Colorectal cancer (CRC) is still one of the most common types of cancer in the world, and the gut microbiome plays an important role in its development. The microbiome is involved in the carcinogenesis, format...
There is a growing level of interest in the potential role inflammation has on the initiation and progression of malignancy. Notable examples include Helicobacter pylori-mediated inflammation in gastric cancer an...
Esophageal squamous cell carcinoma (ESCC) is the major type of esophageal cancer in China. The role of the bacteria present in ESCC tissue in neoplastic progression has not been fully elucidated. This study ai...
Colorectal cancer (CRC) screening reduces CRC incidence and mortality. However, current screening methods are either hampered by invasiveness or suboptimal performance, limiting their effectiveness as primary ...
Colorectal cancer which is related to genetic and environmental risk factors, is among the most prevalent life-threatening cancers. Although several pathogenic bacteria are associated with colorectal cancer et...
Though the gut microbiome has been associated with efficacy of immunotherapy (ICI) in certain cancers, similar findings have not been identified for microbiomes from other body sites and their correlation to t...
Most NSCLCs metastasised out of the lungs at the time of diagnosis and cannot be surgically removed . Cytotoxic chemotherapy drugs have become the main treatment in recent decades, especially in patients with ...
The gut microbiota influences many aspects of host physiology, including immune regulation, and is predictive of outcomes in cancer patients. However, whether conventional myelosuppressive chemotherapy affects...
Host tissue infections by bacteria and viruses can cause cancer. Known viral carcinogenic mechanisms are disruption of the host genome via genomic integration and expression of oncogenic viral proteins. An imp...
Emerging evidence implicates the gut microbiome in liver inflammation and hepatocellular carcinoma (HCC) development. We aimed to characterize the temporal evolution of gut dysbiosis, in relation to the phenot...
Triazole, polyene, and echinocandin antifungal agents are extensively used to treat invasive fungal infections (IFIs); however, the optimal prophylaxis option is not clear. This study aimed to determine the op...
Colorectal cancer is a leading cause of cancer-related deaths worldwide. The human gut microbiome has become an active area of research for understanding the initiation, progression, and treatment of colorecta...
Composition and maintenance of the microbiome is vital to gut homeostasis. However, there is limited knowledge regarding the impact of high doses of radiation, which can occur as a result of cancer radiation t...
Gastric cancer (GC) is one of the most common malignancies causing death worldwide, and Helicobacter pylori is a powerful inducer of precancerous lesions and GC. The oral microbiota is a complex ecosystem and is ...
Increase in the number of infections caused by Gram-negative bacteria in neutropenic cancer patients has prompted the search for novel therapeutic agents having dual anticancer and antimicrobial properties. Ba...
The dysregulation of gut microbiota is pivotal in colorectal carcinogenesis. Meanwhile, altered gut microbiome may affect the development of intestinal diseases through interaction with the host genes. However...
Alteration in gut microbiota has been recently linked with childhood leukemia and the use of chemotherapy. Whether the perturbed microbiota community is restored after disease remission and cessation of cancer...
The gut microbiota is an important modulator of immune, metabolic, psychological and cognitive mechanisms. Chemotherapy adversely affects the gut microbiota, inducing acute dysbiosis, and alters physiological ...
Mouse and human studies support the promise of dry beans to improve metabolic health and to lower cancer risk. In overweight/obese patients with a history of colorectal polyps or cancer, the Beans to Enrich th...
Enterotoxigenic Bacteroides fragilis (ETBF) is an enterotoxin-producing bacterium that possibily has a role in the occurrence and progression of colorectal cancer (CRC) by modulating the mucosal immune response a...
Breast cancer ranks first in women, and is the second cause of death in this gender. In addition to genetics, the environment contributes to the development of the disease, although the factors involved are no...
A causal association has been suggested between certain bacteria and colorectal cancer (CRC). Only a few studies have, however, investigated the presence of these bacteria directly in colon tissue with conflic...
With microbiome research moving from a predominantly data-driven field towards understanding its contribution at a more mechanistic level, the impact of the microbiome on health and human disease has surfaced. At the same time, cancer research has diversified its approach with increasing emphasis for a multifaceted treatment model to ensure effective treatment towards a cure. As the intersection of the two fields, the role of the microbiome in cancer disease predisposition, risk, initiation, progression, diagnosis, prognosis and treatment is becoming increasingly apparent and a new focus of research. In recognition of this important and growing field of research, we hereby present a collection of primary research articles and reviews on the topic of ‘Microbiome and cancer’.
Submissions broadly cover the following research areas:
The collection was open to submissions from January 2021 up to May 2022.
The intestinal microbiota is a vital organ critical to the development, functioning, and health of the human the host. The Staley Lab at University of Minnesota research focus is to characterize how disruptions in this community affect the onset and progression of diseases and conditions e.g., obesity, colorectal cancer, and inflammatory bowel diseases. By applying microbial ecology principles and leveraging next-generation sequencing technologies, their goal is to develop targeted, microbiota-based therapies to improve patient outcomes. Chris is a Senior Board Member for BMC Microbiology.
Jacques Ravel is a Professor in the Department of Microbiology and Immunology and the Associate Director for Genomics at the Institute for Genome Sciences, University of Maryland School of Medicine in Baltimore, MD. His research program is focused on applying modern genomics technologies and ecological principles to characterize the role and dynamics of the microbial communities inhabiting the human body in health and disease and better define the interactions between the host, the microbes and the environment that drive these ecological systems.
Sean Devlin is a Assistant Professor in Biostatistics as Memorial Sloan Kettering Cancer Centre. His research interests are in the development of adaptive and nonparametric regression methods for cancer research. He was involved in developing a novel algorithm to refine and improve the discriminatory ability of an existing prognostic classifier by incorporating new genomic markers for censored survival data. His current research interests also include developing risk scores for high dimensional survival data when multiple markers may predict treatment response. Sean is a Senior Board Member for BMC Cancer.